Sanofi’s Dupilumab Study: A Potential Game-Changer for Chronic Pruritus Treatment

Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.

Study Overview: Sanofi is conducting a clinical study titled ‘Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO).’ The study aims to evaluate the efficacy and safety of dupilumab in treating adults with CPUO, a condition characterized by severe itching without a known cause. This research is significant as it could provide a new treatment option for patients suffering from this challenging condition.

Intervention/Treatment: The study tests the drug Dupilumab, administered subcutaneously, alongside a non-sedative antihistamine and a moisturizer. Dupilumab is designed to reduce inflammation and alleviate symptoms of chronic pruritus.

Study Design: This Phase 3 study is interventional, with a randomized, parallel assignment. It employs a quadruple masking approach, meaning the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose is treatment.

Study Timeline: The study began on February 15, 2022. The primary completion and estimated study completion dates have not been specified, but the last update was submitted on August 19, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

Market Implications: The ongoing study could influence Sanofi’s stock performance positively if dupilumab proves effective, as it would expand the drug’s market potential. Investors should watch for updates, as successful results could enhance Sanofi’s competitive position in the dermatology market.

The study is currently recruiting, with further details available on the ClinicalTrials portal.